SCHEMBL15573077

SCHEMBL15573077

CNC(=O)c1cc(Oc2ccc(CNC(=O)Nc3ccccc3OC)cc2)ccn1

nearest known ligand 0.65

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
DDR2 Q16832 2/20 0.65
RAF1 P04049 4/20 0.56
HDAC1 Q13547 2/20 0.55
HDAC6 Q9UBN7 2/20 0.55
HDAC11 Q96DB2 1/20 0.55
CSF1R P07333 1/20 0.54
PYGL P06737 1/20 0.51
PYGM P11217 1/20 0.51
BRAF P15056 3/20 0.50
NAMPT P43490 1/20 0.50
ALDH1A1 P00352 1/20 0.50
L3MBTL1 Q9Y468 1/20 0.50
KDR P35968 3/20 0.49
MAPK14 Q16539 1/20 0.49
EPHX2 P34913 1/20 0.48
KMT2A Q03164 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15574556 0.91 DDR2 (0.70) DDR2RAF1CSF1RBRAFALDH1A1
SCHEMBL16990693 0.90 HDAC1 (0.55) DDR2RAF1HDAC1HDAC6HDAC11
SCHEMBL15573192 0.89 DDR2 (0.54) DDR2RAF1CSF1RPYGLPYGM
SCHEMBL13603627 0.89 DDR2 (0.70) DDR2RAF1CSF1RBRAFALDH1A1
SCHEMBL13603632 0.88 DDR2 (0.72) DDR2RAF1CSF1RBRAFALDH1A1
SCHEMBL15574169 0.88 DDR2 (0.82) DDR2RAF1CSF1RBRAFALDH1A1
SCHEMBL17000011 0.88 DDR2 (0.69) DDR2RAF1CSF1RBRAFALDH1A1
SCHEMBL13603476 0.88 DDR2 (0.57) DDR2RAF1CSF1RBRAFKDR
SCHEMBL169207 0.87 DDR2 (0.59) DDR2RAF1HDAC1HDAC6HDAC11
SCHEMBL13603469 0.87 DDR2 (0.52) DDR2RAF1BRAFKDRMAPK14

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20150225369-A1 DDR2 INHIBITORS FOR THE TREATMENT OF OSTEOARTHRITIS MERCK PATENT GMBH (DE) 2015-08-13 US claimed
EP-2890380-A2 DDR2 INHIBITORS FOR THE TREATMENT OF OSTEOARTHRITIS Merck Patent GmbH (DE) 2015-07-08 EP claimed
WO-2014032755-A2 DDR2 INHIBITORS FOR THE TREATMENT OF OSTEOARTHRITIS MERCK PATENT GMBH (DE) 2014-03-06 WO claimed
US-20150225369-A1 DDR2 INHIBITORS FOR THE TREATMENT OF OSTEOARTHRITIS MERCK PATENT GMBH (DE) 2015-08-13 US disclosed
US-20150225369-A1 DDR2 INHIBITORS FOR THE TREATMENT OF OSTEOARTHRITIS MERCK PATENT GMBH (DE) 2015-08-13 US disclosed
US-20150225369-A1 DDR2 INHIBITORS FOR THE TREATMENT OF OSTEOARTHRITIS MERCK PATENT GMBH (DE) 2015-08-13 US disclosed
EP-2890380-A2 DDR2 INHIBITORS FOR THE TREATMENT OF OSTEOARTHRITIS Merck Patent GmbH (DE) 2015-07-08 EP disclosed
WO-2014032755-A2 DDR2 INHIBITORS FOR THE TREATMENT OF OSTEOARTHRITIS MERCK PATENT GMBH (DE) 2014-03-06 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150225369-A1 DDR2 INHIBITORS FOR THE TREATMENT OF OSTEOARTHRITIS DDR2, DDR1, DDRGK1 DDR2 1/4885RAF1 3072/4885HDAC1 2366/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.